David Holveck was appointed president, CEO, and a director of Endo in April 2008. Prior to joining Endo, Mr. Holveck was president of Johnson & Johnson Development Corporation and vice president, corporate development of Johnson & Johnson since 2004. Mr. Holveck joined Johnson & Johnson as a company group chairman in 1999, following the acquisition of Centocor, Inc., by Johnson & Johnson. Mr. Holveck was CEO of Centocor, Inc. at the time of the acquisition.

Mr. Holveck joined Centocor in 1983, and progressed through various executive positions. In 1992, he assumed the role of president and chief operating officer and later that year was named president and CEO. Prior to joining Centocor, he held positions at General Electric Company, Corning Glass Works, and Abbott Laboratories. Mr. Holveck is a member of the Board of Trustees for the Fund for West Chester University and the Board of Directors of the Eastern Technology Council, as well as the Board of Directors of Light Sciences Oncology, Inc.

Mr. Holveck's address will focus on the challenge of balancing growth and innovation in the rapidly evolving health care landscape. 

Fred Hassan is chairman of the board and CEO of Schering-Plough Corporation. Prior to joining Schering-Plough in April 2003, and assuming his current position, Mr. Hassan was chairman and CEO of Pharmacia Corporation. He joined the former Pharmacia & Upjohn in May 1997, as CEO and was elected to the Board of Directors. In February 2001, Mr. Hassan was named chairman of the Board of Pharmacia, the company created through the merger of the former Monsanto and Pharmacia & Upjohn companies.

Previously, Mr. Hassan was executive vice president of Wyeth, formerly known as American Home Products, with responsibility for its pharmaceutical and medical products business. He was elected to Wyeth's Board of Directors in 1995. Earlier in his career, Mr. Hassan spent 17 years with Sandoz Pharmaceuticals (now Novartis) and headed its U.S. pharmaceuticals business.

Mr. Hassan received a B.S. degree in chemical engineering from the Imperial College of Science and Technology at the University of London and an MBA from Harvard Business School.

Mr. Hassan is the past chairman of the Board of Directors of the Pharmaceutical Research and Manufacturers of America (PhRMA) and is the immediate past chairman of the HealthCare Institute of New Jersey. He is currently president of the International Federation of Pharmaceutical Manufacturers Associations. In addition, he serves on the Board of Directors of Avon Products, Inc.

Mr. Hassan will engage in an intimate "fireside chat" on the theme "Leadership in a Time of Change:  The Next 10 Years in Biotech."  There will be ample opportunities for participation by the audience.